• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将知识图谱集成到机器学习模型中,以预测非小细胞肺癌患者的生存情况并发现生物标志物。

Integrating knowledge graphs into machine learning models for survival prediction and biomarker discovery in patients with non-small-cell lung cancer.

机构信息

Oncology Data Science, Oncology R&D, AstraZeneca, Waltham, MA, USA.

Oncology Data Science, Oncology R&D, AstraZeneca, South San Francisco, CA, USA.

出版信息

J Transl Med. 2024 Aug 5;22(1):726. doi: 10.1186/s12967-024-05509-9.

DOI:10.1186/s12967-024-05509-9
PMID:39103897
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11302075/
Abstract

Accurate survival prediction for Non-Small Cell Lung Cancer (NSCLC) patients remains a significant challenge for the scientific and clinical community despite decades of advanced analytics. Addressing this challenge not only helps inform the critical aspects of clinical study design and biomarker discovery but also ensures that the 'right patient' receives the 'right treatment'. However, survival prediction is a highly complex task, given the large number of 'omics; and clinical features, as well as the high degree of freedom that drive patient survival. Prior knowledge could play a critical role in uncovering the complexity of a disease and understanding the driving factors affecting a patient's survival. We introduce a methodology for incorporating prior knowledge into machine learning-based models for prediction of patient survival through Knowledge Graphs, demonstrating the advantage of such an approach for NSCLC patients. Using data from patients treated with immuno-oncologic therapies in the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials, we found that the use of knowledge graphs yielded significantly improved hazard ratios, including in the POPLAR cohort, for models based on biomarker tumor mutation burden compared with those based on knowledge graphs. Use of a model-defined mutational 10-gene signature led to significant overall survival differentiation for both trials. We provide parameterized code for incorporating knowledge graphs into survival analyses for use by the wider scientific community.

摘要

尽管经过了几十年的高级分析,准确预测非小细胞肺癌(NSCLC)患者的生存率仍然是科学界和临床界面临的重大挑战。解决这一挑战不仅有助于为临床研究设计和生物标志物发现的关键方面提供信息,还确保“合适的患者”接受“合适的治疗”。然而,由于存在大量的“组学”和临床特征,以及驱动患者生存的高度自由度,因此生存预测是一项非常复杂的任务。先验知识在揭示疾病的复杂性和理解影响患者生存的驱动因素方面可以发挥关键作用。我们介绍了一种通过知识图谱将先验知识纳入基于机器学习的患者生存预测模型的方法,展示了这种方法在 NSCLC 患者中的优势。通过使用来自接受免疫肿瘤治疗的患者的数据,在 POPLAR(NCT01903993)和 OAK(NCT02008227)临床试验中,我们发现与基于知识图谱的模型相比,基于生物标志物肿瘤突变负担的模型使用知识图谱可显著提高风险比,包括在 POPLAR 队列中。使用模型定义的突变 10 基因特征可显著区分两个试验的总生存期。我们提供了将知识图谱纳入生存分析的参数化代码,以供更广泛的科学界使用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e9d/11302075/b2bbcbdd6b11/12967_2024_5509_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e9d/11302075/5339166338ae/12967_2024_5509_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e9d/11302075/4c93c4299b93/12967_2024_5509_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e9d/11302075/3a3dea151e12/12967_2024_5509_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e9d/11302075/c5f728f12d9b/12967_2024_5509_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e9d/11302075/b2bbcbdd6b11/12967_2024_5509_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e9d/11302075/5339166338ae/12967_2024_5509_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e9d/11302075/4c93c4299b93/12967_2024_5509_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e9d/11302075/3a3dea151e12/12967_2024_5509_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e9d/11302075/c5f728f12d9b/12967_2024_5509_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e9d/11302075/b2bbcbdd6b11/12967_2024_5509_Fig5_HTML.jpg

相似文献

1
Integrating knowledge graphs into machine learning models for survival prediction and biomarker discovery in patients with non-small-cell lung cancer.将知识图谱集成到机器学习模型中,以预测非小细胞肺癌患者的生存情况并发现生物标志物。
J Transl Med. 2024 Aug 5;22(1):726. doi: 10.1186/s12967-024-05509-9.
2
Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.肿瘤蛋白 p53 和共济失调毛细血管扩张突变与非小细胞肺癌患者免疫检查点抑制剂反应和死亡率的关联。
JAMA Netw Open. 2019 Sep 4;2(9):e1911895. doi: 10.1001/jamanetworkopen.2019.11895.
3
Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.开发和验证一种机器学习模型,以探索 IV 期 EGFR 突变阳性非小细胞肺癌患者对酪氨酸激酶抑制剂的反应。
JAMA Netw Open. 2020 Dec 1;3(12):e2030442. doi: 10.1001/jamanetworkopen.2020.30442.
4
Machine-Learning and Stochastic Tumor Growth Models for Predicting Outcomes in Patients With Advanced Non-Small-Cell Lung Cancer.用于预测晚期非小细胞肺癌患者预后的机器学习与随机肿瘤生长模型
JCO Clin Cancer Inform. 2019 Sep;3:1-11. doi: 10.1200/CCI.19.00046.
5
The Association Between Tumor Burden and the Efficacy of Immunotherapy Among Patients With Non-small Cell Lung Cancer.非小细胞肺癌患者肿瘤负荷与免疫治疗疗效之间的关联
Cancer Control. 2025 Jan-Dec;32:10732748251320822. doi: 10.1177/10732748251320822.
6
Deep Learning for Prediction of N2 Metastasis and Survival for Clinical Stage I Non-Small Cell Lung Cancer.深度学习预测临床Ⅰ期非小细胞肺癌 N2 转移和生存。
Radiology. 2022 Jan;302(1):200-211. doi: 10.1148/radiol.2021210902. Epub 2021 Oct 26.
7
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性:一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
8
Discovery of mutations predictive of survival benefit from immunotherapy in first-line NSCLC: A retrospective machine learning study of IMpower150 liquid biopsy data.一线非小细胞肺癌中预测免疫治疗生存获益的突变发现:一项对IMpower150液体活检数据的回顾性机器学习研究
Comput Biol Med. 2025 May;189:109964. doi: 10.1016/j.compbiomed.2025.109964. Epub 2025 Mar 4.
9
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.抗 PD-1 治疗在非小细胞肺癌中的反应的表观遗传学预测:多中心回顾性分析。
Lancet Respir Med. 2018 Oct;6(10):771-781. doi: 10.1016/S2213-2600(18)30284-4. Epub 2018 Aug 9.
10
Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.KRAS突变在接受免疫检查点抑制剂治疗的晚期非小细胞肺癌中的预后价值:一项荟萃分析与综述
Oncotarget. 2017 Jul 18;8(29):48248-48252. doi: 10.18632/oncotarget.17594.

本文引用的文献

1
Deep multimodal graph-based network for survival prediction from highly multiplexed images and patient variables.基于深度多模态图的网络,用于从高度多重化的图像和患者变量中进行生存预测。
Comput Biol Med. 2023 Mar;154:106576. doi: 10.1016/j.compbiomed.2023.106576. Epub 2023 Feb 1.
2
Building a knowledge graph to enable precision medicine.构建知识图谱以实现精准医学。
Sci Data. 2023 Feb 2;10(1):67. doi: 10.1038/s41597-023-01960-3.
3
Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer.
基于知识图谱的推荐框架识别 EGFR 突变型非小细胞肺癌耐药的驱动因素。
Nat Commun. 2022 Mar 29;13(1):1667. doi: 10.1038/s41467-022-29292-7.
4
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.25000 例患者前瞻性临床测序的转移模式的基因组特征分析。
Cell. 2022 Feb 3;185(3):563-575.e11. doi: 10.1016/j.cell.2022.01.003.
5
Co-occurring genomic alterations and immunotherapy efficacy in NSCLC.非小细胞肺癌中同时发生的基因组改变与免疫治疗疗效
NPJ Precis Oncol. 2022 Jan 18;6(1):4. doi: 10.1038/s41698-021-00243-7.
6
KGDAL: Knowledge Graph Guided Double Attention LSTM for Rolling Mortality Prediction for AKI-D Patients.KGDAL:用于急性肾损伤-透析患者滚动死亡率预测的知识图谱引导双注意力长短期记忆网络
ACM BCB. 2021 Aug;2021. doi: 10.1145/3459930.3469513.
7
Long-term cancer survival prediction using multimodal deep learning.基于多模态深度学习的癌症长期生存预测。
Sci Rep. 2021 Jun 29;11(1):13505. doi: 10.1038/s41598-021-92799-4.
8
Prediction and interpretation of cancer survival using graph convolution neural networks.基于图卷积神经网络的癌症生存预测和解释。
Methods. 2021 Aug;192:120-130. doi: 10.1016/j.ymeth.2021.01.004. Epub 2021 Jan 21.
9
Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials.阿特珠单抗对比多西他赛用于治疗晚期 NSCLC 患者:POPLAR 和 OAK 两项随机、2 期和 3 期临床试验的最终结果。
J Thorac Oncol. 2021 Jan;16(1):140-150. doi: 10.1016/j.jtho.2020.09.022. Epub 2020 Nov 6.
10
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.肿瘤突变负荷作为实体瘤的预测性生物标志物。
Cancer Discov. 2020 Dec;10(12):1808-1825. doi: 10.1158/2159-8290.CD-20-0522. Epub 2020 Nov 2.